NCCN Guidelines® insights: Non-Hodgkin's lymphomas, version 3.2016 featured updates to the NCCN guidelines

Steven M. Horwitz; Andrew D. Zelenetz; Leo I. Gordon; William G. Wierda; Jeremy S. Abramson; Ranjana H. Advani; C. Babis Andreadis; Nancy Bartlett; John C. Byrd; Luis E. Fayad; Richard I. Fisher; Martha J. Glenn; Thomas M. Habermann; Nancy Lee Harris; Francisco Hernandez-Ilizaliturri; Richard T. Hoppe; Mark S. Kaminski; Christopher R. Kelsey; Youn H. Kim; Susan Krivacic; Ann S. La Casce; Matthew Lunning; Auayporn Nademanee; Oliver Press; Rachel Rabinovitch; Nishitha Reddy; Erin Reid; Kenneth Roberts; Ayman A. Saad; Lubomir Sokol; Lode J. Swinnen; Julie M. Vose; Joachim Yahalom; Nadeem Zafar; Mary Dwyer; Hema Sundar; Pierluigi Porcu

doi:10.6004/jnccn.2016.0117

NCCN Guidelines® insights: Non-Hodgkin's lymphomas, version 3.2016 featured updates to the NCCN guidelines

Steven M. Horwitz, Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Mark S. Kaminski, Christopher R. Kelsey, Youn H. Kim, Susan KrivacicAnn S. La Casce, Matthew Lunning, Auayporn Nademanee, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, Hema Sundar, Pierluigi Porcu

Hematology

Research output: Contribution to journal › Review article › peer-review

67 Scopus citations

Abstract

Peripheral T-cell lymphomas (PTCLs) represent a relatively uncommon heterogeneous group of non-Hodgkin's lymphomas (NHLs) with an aggressive clinical course and poor prognosis. Anthracycline-based multiagent chemotherapy with or without radiation therapy followed by first-line consolidation with high-dose therapy followed by autologous stem cell rescue (HDT/ASCR) is the standard approach to most of the patients with newly diagnosed PTCL. Relapsed or refractory disease is managed with second-line systemic therapy followed by HDT/ASCR or allogeneic stem cell transplant, based on the patient's eligibility for transplant. In recent years, several newer agents have shown significant activity in patients with relapsed or refractory disease across all 4 subtypes of PTCL. These NCCN Guideline Insights highlight the important updates to the NCCN Guidelines for NHL, specific to the management of patients with relapsed or refractory PTCL.

Original language	English (US)
Pages (from-to)	1067-1079
Number of pages	13
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	14
Issue number	9
DOIs	https://doi.org/10.6004/jnccn.2016.0117
State	Published - Sep 2016

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2016.0117

Cite this

Horwitz, S. M., Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Byrd, J. C., Fayad, L. E., Fisher, R. I., Glenn, M. J., Habermann, T. M., Harris, N. L., Hernandez-Ilizaliturri, F., Hoppe, R. T., Kaminski, M. S., Kelsey, C. R., Kim, Y. H., ... Porcu, P. (2016). NCCN Guidelines® insights: Non-Hodgkin's lymphomas, version 3.2016 featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 14(9), 1067-1079. https://doi.org/10.6004/jnccn.2016.0117

Horwitz, SM, Zelenetz, AD, Gordon, LI, Wierda, WG, Abramson, JS, Advani, RH, Andreadis, CB, Bartlett, N, Byrd, JC, Fayad, LE, Fisher, RI, Glenn, MJ, Habermann, TM, Harris, NL, Hernandez-Ilizaliturri, F, Hoppe, RT, Kaminski, MS, Kelsey, CR, Kim, YH, Krivacic, S, La Casce, AS, Lunning, M, Nademanee, A, Press, O, Rabinovitch, R, Reddy, N, Reid, E, Roberts, K, Saad, AA, Sokol, L, Swinnen, LJ, Vose, JM, Yahalom, J, Zafar, N, Dwyer, M, Sundar, H & Porcu, P 2016, 'NCCN Guidelines® insights: Non-Hodgkin's lymphomas, version 3.2016 featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 14, no. 9, pp. 1067-1079. https://doi.org/10.6004/jnccn.2016.0117

@article{7e61548664e54188a3a46e6f881ac18b,

title = "NCCN Guidelines{\textregistered} insights: Non-Hodgkin's lymphomas, version 3.2016 featured updates to the NCCN guidelines",

abstract = "Peripheral T-cell lymphomas (PTCLs) represent a relatively uncommon heterogeneous group of non-Hodgkin's lymphomas (NHLs) with an aggressive clinical course and poor prognosis. Anthracycline-based multiagent chemotherapy with or without radiation therapy followed by first-line consolidation with high-dose therapy followed by autologous stem cell rescue (HDT/ASCR) is the standard approach to most of the patients with newly diagnosed PTCL. Relapsed or refractory disease is managed with second-line systemic therapy followed by HDT/ASCR or allogeneic stem cell transplant, based on the patient's eligibility for transplant. In recent years, several newer agents have shown significant activity in patients with relapsed or refractory disease across all 4 subtypes of PTCL. These NCCN Guideline Insights highlight the important updates to the NCCN Guidelines for NHL, specific to the management of patients with relapsed or refractory PTCL.",

author = "Horwitz, {Steven M.} and Zelenetz, {Andrew D.} and Gordon, {Leo I.} and Wierda, {William G.} and Abramson, {Jeremy S.} and Advani, {Ranjana H.} and Andreadis, {C. Babis} and Nancy Bartlett and Byrd, {John C.} and Fayad, {Luis E.} and Fisher, {Richard I.} and Glenn, {Martha J.} and Habermann, {Thomas M.} and Harris, {Nancy Lee} and Francisco Hernandez-Ilizaliturri and Hoppe, {Richard T.} and Kaminski, {Mark S.} and Kelsey, {Christopher R.} and Kim, {Youn H.} and Susan Krivacic and {La Casce}, {Ann S.} and Matthew Lunning and Auayporn Nademanee and Oliver Press and Rachel Rabinovitch and Nishitha Reddy and Erin Reid and Kenneth Roberts and Saad, {Ayman A.} and Lubomir Sokol and Swinnen, {Lode J.} and Vose, {Julie M.} and Joachim Yahalom and Nadeem Zafar and Mary Dwyer and Hema Sundar and Pierluigi Porcu",

note = "Publisher Copyright: {\textcopyright} JNCCN-Journal of the National Comprehensive Cancer Network.",

year = "2016",

month = sep,

doi = "10.6004/jnccn.2016.0117",

language = "English (US)",

volume = "14",

pages = "1067--1079",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "9",

}

TY - JOUR

T1 - NCCN Guidelines® insights

T2 - Non-Hodgkin's lymphomas, version 3.2016 featured updates to the NCCN guidelines

AU - Horwitz, Steven M.

AU - Zelenetz, Andrew D.

AU - Gordon, Leo I.

AU - Wierda, William G.

AU - Abramson, Jeremy S.

AU - Advani, Ranjana H.

AU - Andreadis, C. Babis

AU - Bartlett, Nancy

AU - Byrd, John C.

AU - Fayad, Luis E.

AU - Fisher, Richard I.

AU - Glenn, Martha J.

AU - Habermann, Thomas M.

AU - Harris, Nancy Lee

AU - Hernandez-Ilizaliturri, Francisco

AU - Hoppe, Richard T.

AU - Kaminski, Mark S.

AU - Kelsey, Christopher R.

AU - Kim, Youn H.

AU - Krivacic, Susan

AU - La Casce, Ann S.

AU - Lunning, Matthew

AU - Nademanee, Auayporn

AU - Press, Oliver

AU - Rabinovitch, Rachel

AU - Reddy, Nishitha

AU - Reid, Erin

AU - Roberts, Kenneth

AU - Saad, Ayman A.

AU - Sokol, Lubomir

AU - Swinnen, Lode J.

AU - Vose, Julie M.

AU - Yahalom, Joachim

AU - Zafar, Nadeem

AU - Dwyer, Mary

AU - Sundar, Hema

AU - Porcu, Pierluigi

PY - 2016/9

Y1 - 2016/9

N2 - Peripheral T-cell lymphomas (PTCLs) represent a relatively uncommon heterogeneous group of non-Hodgkin's lymphomas (NHLs) with an aggressive clinical course and poor prognosis. Anthracycline-based multiagent chemotherapy with or without radiation therapy followed by first-line consolidation with high-dose therapy followed by autologous stem cell rescue (HDT/ASCR) is the standard approach to most of the patients with newly diagnosed PTCL. Relapsed or refractory disease is managed with second-line systemic therapy followed by HDT/ASCR or allogeneic stem cell transplant, based on the patient's eligibility for transplant. In recent years, several newer agents have shown significant activity in patients with relapsed or refractory disease across all 4 subtypes of PTCL. These NCCN Guideline Insights highlight the important updates to the NCCN Guidelines for NHL, specific to the management of patients with relapsed or refractory PTCL.

AB - Peripheral T-cell lymphomas (PTCLs) represent a relatively uncommon heterogeneous group of non-Hodgkin's lymphomas (NHLs) with an aggressive clinical course and poor prognosis. Anthracycline-based multiagent chemotherapy with or without radiation therapy followed by first-line consolidation with high-dose therapy followed by autologous stem cell rescue (HDT/ASCR) is the standard approach to most of the patients with newly diagnosed PTCL. Relapsed or refractory disease is managed with second-line systemic therapy followed by HDT/ASCR or allogeneic stem cell transplant, based on the patient's eligibility for transplant. In recent years, several newer agents have shown significant activity in patients with relapsed or refractory disease across all 4 subtypes of PTCL. These NCCN Guideline Insights highlight the important updates to the NCCN Guidelines for NHL, specific to the management of patients with relapsed or refractory PTCL.

UR - http://www.scopus.com/inward/record.url?scp=84985996094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84985996094&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2016.0117

DO - 10.6004/jnccn.2016.0117

M3 - Review article

C2 - 27587620

AN - SCOPUS:84985996094

SN - 1540-1405

VL - 14

SP - 1067

EP - 1079

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 9

ER -

NCCN Guidelines® insights: Non-Hodgkin's lymphomas, version 3.2016 featured updates to the NCCN guidelines

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this